Revolution Medicines Stock Rises 39% Over Positive Topline Data From Daraxonrasib Study

Revolution Medicines shares are up about 39% after positive topline data from the Phase 3 RASolute trial for Daraxonrasib in metastatic pancreatic ductal adenocarcinoma. The result is a major clinical readout for the company and materially improves the drug's prospects in a large, high-need oncology market. The move is likely to have a meaningful company-specific impact and may also lift sentiment across select biotech names.

Analysis

Revolution Medicines shares are up about 39% after positive topline data from the Phase 3 RASolute trial for Daraxonrasib in metastatic pancreatic ductal adenocarcinoma. The result is a major clinical readout for the company and materially improves the drug's prospects in a large, high-need oncology market. The move is likely to have a meaningful company-specific impact and may also lift sentiment across select biotech names.